Comment: The quality of evidence is downgraded by study limitations (unclear allocation concealment, unclear blinding, unclear selective outcome reporting in many studies), by imprecise results (few patients for each comparison).
A Cochrane review [Abstract] 1 included 6 studies with a total of 542 subjects. These trials assessed the effectiveness of hormonal therapy in women with advanced or recurrent endometrial cancer as a single agent, as part of combination therapy and as low versus high dose. All comparisons were restricted to single-trial analyses and were underpowered to find evidence that hormonal therapy as a single agent or as a combination treatment prolonged overall or five-year disease-free survival of women with advanced or recurrent endometrial cancer. However, low-dose hormonal therapy may have had a benefit in terms of overall and progression-free survival (PFS) compared to high-dose hormonal therapy (HR 1.31, 95% CI 1.04 to 1.66 and HR 1.35, 95% CI 1.07 to 1.71 for overall and PFS, respectively). None of the trials reported quality of life as an outcome.
Date of latest search: 9 November 2010
Primary/Secondary Keywords